Risk of disease progression in low-risk MDS is linked to distinct epigenetic subtypes

Leukemia. 2019 Nov;33(11):2753-2757. doi: 10.1038/s41375-019-0518-5. Epub 2019 Jul 22.

Tingting Qin¹, Jason Sotzen², Raajit K Rampal^{3

4}, Franck T Rapaport⁵, Ross L Levine^{3

4}, Virginia Klimek⁴, Stephen D Nimer^{6

7}, Maria E Figueroa^{8

9}

¹ University of Michigan Medical School, Department of Computational Medicine and Bioinformatics, Ann Arbor, MI, 48109, USA.
² University of Michigan Medical School, Department of Pathology, Ann Arbor, MI, 48109, USA.
³ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
⁴ Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA.
⁵ Center for Hematologic Malignancies, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA.
⁶ Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA.
⁷ Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA.
⁸ Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA. mef162@miami.edu.
⁹ Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA. mef162@miami.edu.

No abstract available

Publication types